COMUNICADO: La Comisión Europea aprueba IMBRUVICA(TM) para dos cánceres sanguíneos (y 3)

1) Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK

inhibitors in clinical development. J Hematol Oncol 2013;6:59.

2) European Medicines Agency. Committee for Medicinal Products for Human Use:

Summary of opinion. Disponible en:

http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003791/WC500170191.pdf

!

_http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/07/news_

detail_002142.jsp&mid=WC0b01ac058004d5c1. Consultado en octubre de 2014.

3) American Cancer Society. What is chronic lymphocytic leukemia? Disponible en:

http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-what-is-cll

. Consultado en julio de 2014.

4) Schnaiter A, Stilgenbauer S. 17p Deletion in chronic lymphocytic leukemia:

risk stratification and therapeutic approach. Hematol Oncol Clin N Am 2013;27:289-301.

5) McKay P, Leach M, Jackson R, et al. Guidelines for the investigation and

management of mantle cell lymphoma. Br J Haematol. 2012;159:405-26.

6) Williams ME, Dreyling M, Winter J, Muneer S, Leonard JP. Management of mantle

cell lymphoma: key challenges and next steps. Clin Lymphoma Myeloma Leuk.

2010;10:336-46.

7) Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in

previously treated chronic lymphoid leukemia. N Engl J Med. 2014 May 31 [epub ahead of

print].

8) IMBRUVICA(TM) (ibrutinib) Summary of Product Characteristics. Octubre de

2014.

9) Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or

refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.

10) European Medicines Agency. How is the medicine expected to work?

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/06/human_orphan_001058.jsp&mid=WC0b01ac058001d12b

. Acceso septiembre de 2014

11) Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines

Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for

diagnosis, treatment and follow-up. Ann Oncol 2011;22(Suppl.6):vi50-4.

12) Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies

in Europe by morphologic subtype: results of the HAEMACARE project. Blood

2010;116:3724-34.

13) Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in

chronic lymphocytic leukemia. Cancer Control 2012;19:18-25.Stilgenbauer S, Zenz T.

Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia. Hematology

2010;481-8.

14) Stilgenbauer S, Zenz T. Understanding and Managing Ultra High-Risk Chronic

Lymphocytic Leukemia. Hematology 2010;481-8.

15) Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline.

Blood. 2013;112(23).

16) Santos FPS, O'Brien S. Small Lymphocytic Lymphoma and Chronic Lymphocytic

Leukemia Are They the Same Disease? The Cancer Journal. 2012;8(5):396-403.

17) Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and

other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011;21:293-8.

18) Leukemia and Lymphoma Society. Mantle cell lymphoma facts. Disponible en:

http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/mantlecelllymphoma.pdf

Last accessed May 14, 2013.

19) Swerdlow SH, Campo E, Muller-Hermelink HK. Mantle cell lymphoma. In:

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein M, Thiele J, Vardiman JW,

editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon,

France: IARC Press; 2008:229-32.

20) Vose, J.M. (2012). Mantle cell lymphoma: 2012 update on diagnosis,

risk-stratification, and clinical management. Am J Hematol. 87(6): 604-9.

21) Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or

refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter

phase 2 PINNACLE study. Ann Oncol 2009;20:520-5.

PHEM/IBR/0814/0006

October 2014

Photo:

http://photos.prnewswire.com/prnh/20140324/NY88746LOGO

Video:

http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cllCONTACTO: Consultas de medios: Satu Kaarina Glawe, Móvil:+49(172)294-6264, E-mail: sglawe@its.jnj.com / Relaciones para inversores:Stan Panasewicz, Tel: +1-732-524-2524 - Louise Mehrotra, Tel:+1-732-524-6491